Key Members of the CmPn as Biomarkers Distinguish Histological and Immune Subtypes of Hepatic Cancers

• Published in: Diagnostics (Basel) Vol. 13; no. 6; p. 1012
• Main Authors: Abou-Fadel, Johnathan, Reid, Victoria, Le, Alexander, Croft, Jacob, Zhang, Jun
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2023; MDPI
• Subjects: Angiogenesis; Antibodies; Antigens; Bioinformatics; Biological markers; Biomarkers; Cancer; Care and treatment; Cellular signal transduction; classic nuclear progesterone receptors; Diagnosis; Genetic aspects; Health aspects; Hepatitis B; Hepatitis C; immunological subtypes; Liver; Liver cancer; liver cancer subtypes; Medical prognosis; Metastasis; non-classic membrane progesterone receptors; Patients; Progesterone; RNA sequencing; Sociology; Tumorigenesis; United States; immunological subtypes; biomarkers; non-classic membrane progesterone receptors; progesterone; liver cancer subtypes; CCM signaling complex (CSC); classic nuclear progesterone receptors; liver cancer; tumorigenesis; mPRs-PRG-nPRs (CmPn) and CSC-mPRs-PRG (CmP) signaling network
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics13061012

Liver cancer, comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), is a leading cause of cancer-related deaths worldwide. The liver is a primary metabolic organ for progesterone (PRG) and PRG exerts its effects through classic nuclear PRG receptors (nPRs) and non-classic membrane PRG receptors (mPRs) or a combination of both. Previous studies have shown that the CCM signaling complex (CSC) couples both nPRs and mPRs to form the CmPn (CSC-mPR-PRG-nPR) signaling network, which is involved in multiple cellular signaling pathways, including tumorigenesis of various cancers. Despite advances in treatment, 5-year survival rates for liver cancer patients remain low, largely due to the chemoresistant nature of HCCs. The lack of sensitive and specific biomarkers for liver cancer diagnosis and prognosis emphasizes the need for identifying new potential biomarkers. We propose the potential use of CmPn members' expression data as prognostic biomarkers or biomarker signatures for the major types of hepatic cancer, including HCCs and CCAs, as well as rare subtypes such as undifferentiated pleomorphic sarcoma (UPS) and hepatic angiosarcoma (HAS). In this study, we investigated the CmPn network through RNAseq data and immunofluorescence techniques to measure alterations to key cancer pathways during liver tumorigenesis. Our findings reveal significant differential expression of multiple CmPn members, including CCM1, PAQR7, PGRMC1, and nPRs, in both HCCs and CCAs, highlighting the crucial roles of mPRs, nPRs, and CSC signaling during liver tumorigenesis. These key members of the CmPn network may serve as potential biomarkers for the diagnosis and prognosis of liver cancer subtypes, including rare subtypes.